Newsroom | 38846 results

Sorted by: Latest

Other Health
-

Hippocratic AI Named to Newsweek’s America’s Greatest Startup Workplaces 2025

PALO ALTO, Calif.--(BUSINESS WIRE)--Hippocratic AI recognized for excellence in workplace culture and sustainable growth through a rigorous evaluation...
-

Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, is presenting preclinical data demonstrating first-in-industry targeted degradation of ERG at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which begins today in Chicago, Illinois. ERG has been a long-recognized high-value target in prostate cancer, where ERG fusio...
-

Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors

BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced that its Phase 1/2 clinical trial of NDI-219216, the company's investigational non-covalent Werner syndrome helicase (WRN) inhibitor, is actively enrolling and dosing patients with advanced solid tumors. "The initiation of this clinical trial marks an important mil...
-

Onchilles Pharma Presents New Data at AACR 2025 Highlighting N17350, a Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma Presents New Data at AACR 2025 Highlighting N17350, a Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway...
-

New Research Explains Why Our Waistlines Expand in Middle Age

LOS ANGELES--(BUSINESS WIRE)--It’s no secret that our waistlines often expand in middle-age, but the problem isn’t strictly cosmetic. Belly fat accelerates aging and slows down metabolism, increasing our risk for developing diabetes, heart problems and other chronic diseases. Exactly how age transforms a six pack into a softer stomach, however, is murky. Now preclinical research by City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United Stat...
-

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

DURHAM, N.C. & MÄNNEDORF, Switzerland--(BUSINESS WIRE)--BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser™, provided by Tecan. The integrated solution enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing growing demand for scalable, multiomi...
-

Claritev and Burjeel Holdings Partner to Advance Revenue Integrity Solutions in the MENA Region

MCLEAN, Va. & ABU DHABI, United Arab Emirates--(BUSINESS WIRE)--Claritev Corporation (“Claritev”) (NYSE: CTEV) and Claims Care Revenue Cycle Management LLC (“Claims Care” or “CCRCM”), a division of Burjeel Holdings (ADX: BURJEEL), have signed a memorandum of understanding (MOU) to leverage Claritev’s Payment and Revenue Integrity solutions for the Middle East and North Africa regional payer market and create a joint product roadmap to offer advanced revenue cycle management (RCM) capabilities i...
-

HCA Healthcare Reports First Quarter 2025 Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2025. Key first quarter metrics (all percentage changes compare 1Q 2025 to 1Q 2024 unless otherwise noted): Revenues totaled $18.321 billion Net income attributable to HCA Healthcare, Inc. totaled $1.610 billion, or $6.45 per diluted share Adjusted EBITDA totaled $3.733 billion Cash flows from operating activities totaled $1.651 billion Same f...
-

InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). The approval of the first-line CLL/SLL treatment will enable orelabrutinib to benefit an even broader population of lymphoma patients. Orelab...
-

PwC Strategy& Releases Report at IVI RMA Congress Showing Potential of Assisted Reproductive Technology to Mitigate Economic Impact of Demographic Changes in the U.S.

BASKING RIDGE, N.J.--(BUSINESS WIRE)--At the 11th International IVI RMA Congress, hosted by IVI RMA, the world’s leading reproductive medicine group with 200+ Assisted Reproductive Technology (ART) clinics in 15 countries and 22 labs across North America, PwC Strategy& released a report that analyzes the impact of aging populations and sustained low birth rates on economic and social dynamics in the United States and other countries. With fertility rates well below replacement levels and th...